These drugs are called disease-modifying antirheumatic drugs (DMARDs), and they are an important part of an overall treatment plan. Disease-modifying drugs act on the immune system to slow the progression of rheumatoid arthritis. This is why they are called "disease-modifying." Many different drugs can be used as DMARDs in the treatment of RA, but some are used more often than others. Hydroxychloroquine systemic sclerosis Can finger joints heal lupus long term usage hydroxychloroquine Background/Purpose The combination of methotrexate MTX, sulfasalazine SSZ and hydroxychloroquine HCQ triple therapy is a highly effective and well-tolerated treatment in rheumatoid arthritis RA. While MTX is the cornerstone of most successful combination therapies, not all patients are candidates for, or tolerate, MTX. Triple therapy with MTX, sulfasalazine, and hydroxychloroquine etanercept plus MTX People who didn’t show improvement at 24 weeks were switched to the other group. Combination with at least two other DMARDs, such as hydroxychloroquine and sulfasalazine, for a minimum of 12 weeks; OR • Initial use of triple DMARD therapy with methotrexate in combination with at least two other DMARDs, such as hydroxychloroquine and sulfasalazine, for a minimum of 12 weeks. Clinical Notes They are not as powerful as other DMARDs, but they usually cause fewer side effects. Hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine) are used for mild rheumatoid arthritis. Abatacept sulfasalazine hydroxychloroquine triple therapy Treatment of rheumatoid arthritis with methotrexate and., Treating Rheumatoid Arthritis What Is Triple Therapy? Plaquenil depression side effectsPlaquenil retinopathyPlaquenil toxicity in macular oct layer changesPlaquenil and ibuprofen interaction Orencia may be used as monotherapy or concomitantly with methotrexate MTX. • Treatment of adult patients with active psoriatic arthritis PsA Limitations of use Orencia should not be administered concomitantly with TNF antagonists. Orencia is not recommended for use concomitantly with other biologic RA therapy, such as anakinra. Clinical Policy Abatacept Orencia. Health and Community Services ABATACEPT ORENCIA 250 MG VIAL.. Triple Therapy Outperforms Biologics in RA Rheumatology Network. On the basis of the included trials, about 40% of patients naive to methotrexate are expected to have an ACR50 response to oral methotrexate, compared with 60% for triple therapy. Patients may accept this difference in risk and choose methotrexate monotherapy as initial treatment. Conclusions Triple therapy methotrexate plus sulfasalazine plus hydroxychloroquine and most regimens combining biologic DMARDs with methotrexate were effective in controlling disease activity, and all were generally well tolerated in both methotrexate naive and methotrexate exposed patients. Abatacept Orencia is often prescribed after failure of a disease-modifying anti-rheumatic agent DMARD, like methotrexate but it can be used as first-line therapy. Abatacept is used to reduce inflammatory symptoms such as swelling, pain, and stiffness.